AtriCure, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Unless stated otherwise, dollar amounts below are in millions.
Business context
AtriCure develops and sells medical devices for surgical treatment of atrial fibrillation (Afib), left atrial appendage management, and post-operative pain management. Products are sold through direct sales teams and distributors in the United States and international markets. The company reported one operating segment.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $399.2 | $330.4 |
| Gross profit / margin | $300.4 / 75.2% | $245.9 / 74.4% |
| Operating loss / margin | $(26.7) / (6.7)% | $(42.7) / (12.9)% |
| Net loss | $(30.4) | $(46.5) |
| Basic and diluted loss per share | $(0.66) | $(1.02) |
| Net cash from operating activities | $4.5 | $(22.1) |
Revenue grew 20.8% (20.6% on a constant-currency basis). U.S. revenue was $333.5 million, up 20.3%; international revenue was $65.7 million, up 23.5%. By product category, appendage management generated $134.5 million, open ablation $105.3 million, pain management $49.2 million, and minimally invasive ablation $44.6 million.
Gross margin improved 0.8 percentage points, reflecting production efficiencies partly offset by product and geographic mix. Operating expenses rose 13.3% to $327.1 million: R&D increased 28.9% to $73.9 million, and SG&A increased 9.5% to $253.1 million. Management attributed higher R&D costs mainly to staffing, clinical-trial enrollment and regulatory submissions.
Operating cash flow improved by $26.6 million year over year, helped by improved operating results; inventory investment remained a significant use of cash. Investing cash flow was $21.8 million, including a $30.0 million intellectual-property acquisition and net proceeds from investment maturities. Financing cash flow was $(0.03) million.
At year-end, cash and cash equivalents were $84.3 million and short-term investments were $53.0 million, totaling $137.3 million; working capital was $191.7 million. Balance-sheet long-term debt was $60.6 million. On January 5, 2024, the company refinanced the SVB facility with a $125 million asset-based revolving facility, borrowing $61.9 million at closing and reporting approximately $61.9 million of unused availability. The new facility has financial covenants and collateral provisions.
Changes, outlook and notable items
- Revenue increased across all reported product categories and geographies. Cash from operations shifted from negative to positive.
- Net loss narrowed by $16.0 million, but the company remains loss-making, with an accumulated deficit of $357.1 million. Management cites continued spending on sales, product development and clinical programs.
- 2023 results included a $7.5 million gain from a legal settlement and a $3.1 million charge related to an intellectual-property dispute. A $30.0 million patent acquisition was recorded as an intangible asset; the associated payment also settled the dispute and released future royalty obligations.
- The LeAAPS trial, studying prophylactic AtriClip use and stroke prevention, ended 2023 with nearly 1,400 patients enrolled; enrollment and follow-up continue. The company expects $14–17 million of LeAAPS fixed and variable costs over the next 12 months.
- The company launched EPi-Sense ST in 2023 and said it expected to launch its next-generation cryoSPHERE probe in Q1 2024. It provided no clear numerical financial guidance in the supplied filing text.
- Key risks include adoption and reimbursement uncertainty, competition (including Medtronic’s 2023 clearance of the Penditure LAA system), reliance on concentrated suppliers and Ohio manufacturing, regulatory and EU MDR compliance, inflation, and clinical-trial outcomes.
- A relator continues to pursue a qui tam lawsuit alleging kickbacks to healthcare providers; the government declined to intervene. The company contests the allegations and says timing and outcome cannot be predicted.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Important facts for investors to verify
- Whether revenue growth and gross-margin improvement continue, particularly as competition increases.
- Progress, enrollment costs and results of LeAAPS and other clinical trials, and any resulting regulatory or labeling changes.
- Terms, borrowing availability and covenant compliance under the January 2024 credit facility, including interest costs and liquidity requirements.
- Developments and potential financial or operational consequences of the pending qui tam litigation.
- Execution of the planned cryoSPHERE launch and the effect of product mix, inflation and supply-chain constraints on margins and cash flow.